No Data
HOOKIPA Pharma Doses First Patient In Phase 1b Trial Of HIV Therapeutic Vaccine
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study
HOOKIPA Pharma (HOOK) said Monday the first person has been dosed in its phase 1b study of its investigational vaccine HB-500 for the treatment of HIV. The study will evaluate safety and tolerability,
Express News | HOOKIPA Pharma Inc - Under Collaboration Agreement, HOOKIPA Is Responsible for Advancing Hiv Program Through Completion of a Phase 1B Clinical Trial
Express News | HOOKIPA Pharma Inc - HOOKIPA Achieves a $5 Mln Non-Dilutive Milestone Payment Under Its Collaboration and License Agreement With Gilead
Express News | HOOKIPA Pharma Announces First Person Dosed in Phase 1B Clinical Trial of Hb-500 for the Treatment of Hiv
Investors Don't See Light At End Of HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Tunnel And Push Stock Down 25%
HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares have had a horrible month, losing 25% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already held through the l